New cancer pill TQB3122 enters first human tests

NCT ID NCT07269145

Recruiting now Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new oral drug, TQB3122, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow disease. About 86 adults aged 18-75 will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

Beijing Friendship Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100050, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China
Meizhou People's Hospital (Meizhou Academy of Medical Sciences)
NOT_YET_RECRUITING

Meizhou, Guangdong, 514031, China
Shanghai Tenth People's Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200072, China
Sichuan Cancer Hospital
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.